Promising results have been achieved in their implementation in non-alcoholic fatty liver disease and neurodegenerative disorders, as well as in alcohol dependency therapy (31, 32)
Reddit discussions paint a more mixed picture, with pricing transparency coming up most often as a concern
But theres some debate between Novo Nordisk, med spas, and compounding pharmacies about the use of semaglutide, especially compounded semaglutide. Novo Nordisk says it is the only company in the U.S
Retatrutide is still investigational and has not yet become a standard, FDA-approved obesity medication available like semaglutide or tirzepatide
Semaglutide is available in injectable forms as once-weekly subcutaneous injections under brand names including Ozempic (for type 2 diabetes) and Wegovy (for weight management), as well as an oral formulation called Rybelsus (for type 2 diabetes)
Given the clinical evidence reviewed above, patients with type 2 diabetes and/or obesity are the most promising candidate population to benefit from GLP-1RA-centered pharmacotherapy to improve cardiovascular and kidney outcomes